Exenatide prolonged release has been recommended for use with metformin in addition to either a sulphonylurea or a thiazolidinedione. Its use should be restricted to people HbA1c levels above 7.5% and a BMI over 35 or who are unsuitable for insulin therapy, NICE has said.
The draft recommends that long-acting exenatide should only be used for patients unsuitable for triple therapy with any three of: metformin, a sulphonylurea, a thiazolidinedione and a dipeptidyl peptidase-4 inhibitor.
NICE’s draft guidance on long-acting exenatide is open for consultation until 8 November, with final guidance likely to be published in February 2012.
Commenting on the draft decision, Professor Carole Longson, director of the health technology evaluation centre at NICE said: ‘Type-2 diabetes is becoming increasingly more common in adults, so we are pleased to recommend exenatide as a treatment option for some people with the condition.’
Long-acting exenatide is marketed by Eli Lilly as Bydureon suspension for injection.